Prosigna & PAM50 publications

The page lists publications that have assessed the prognostic and predictive power of the PAM50 and Prosigna assays in different patient groups. Publications that compare PAM50 and Prosigna to other tools without having outcomes data are not included.

Prosigna is the commercial implementation of the PAM50 algorithm which evaluates gene expression in breast cancer. The PAM50 assay has been widely reported in the research literature. Clinical studies citing the PAM50 algorithm have used a locally implemented, research-grade assay rather than the more reproducible, clinical-grade assay implemented in Prosigna. The performance of Prosigna has been validated across different samples, runs, laboratories, staff, cancer types and patients.

This page is designed to assist specialist oncologists identify information that may assist in the clinical interpretation of Prosigna results and in the management of their patients’ cancers.

Year                          2020

Title                          Efficacy of Deescalated Chemotherapy According to PAM50 Subtypes, Immune and Proliferation Genes in Triple-Negative Early Breast Cancer: Primary Translational Analysis of the WSG-ADAPT-TN Trial

Ref                            Int J Cancer. 2020 Jan 1;146(1):262-271. doi: 10.1002/ijc.32488.

PubMed ID:           31162838


Year                          2020

Title                          Population-based Study of Prosigna-PAM50 and Outcome Among Postmenopausal Women With Estrogen Receptor-positive and HER2-negative Operable Invasive Lobular or Ductal Breast Cancer

Ref                            Clin Breast Cancer. 2020 Feb 4;S1526-8209(20)30029-X. doi: 10.1016/j.clbc.2020.01.013.

PubMed ID:           32253134


Year                          2020

Title                          The Prosigna 50-gene Profile and Responsiveness to Adjuvant Anthracycline-Based Chemotherapy in High-Risk Breast Cancer Patients

Ref                            NPJ Breast Cancer 2020 Feb 26;6:7. doi: 10.1038/s41523-020-0148-0.

PubMed ID:           32140564


Year                          2019

Title                           Everolimus Plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2

Ref                            Oncologist. 2019 Jul;24(7):893-900. doi: 10.1634/theoncologist.2018-0407.

PubMed ID:           30679318


Year                          2019

Title                           Research-based PAM50 Signature and Long-Term Breast Cancer Survival

Ref                            Breast Cancer Res Treat. 2020 Jan;179(1):197-206. doi: 10.1007/s10549-019-05446-y.

PubMed ID:           31542876


Year                          2019

Title                           PAM50 Subtypes in Baseline and Residual Tumors Following Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer: A Consecutive-Series From a Single Institution

Ref                            Front Oncol. 2019 Aug 6;9:707. doi: 10.3389/fonc.2019.00707.

PubMed ID:           31448227


Year                          2019

Title                          Different Pathological Complete Response Rates According to PAM50 Subtype in HER2+ Breast Cancer Patients Treated With Neoadjuvant Pertuzumab/Trastuzumab vs. Trastuzumab Plus Standard Chemotherapy: An Analysis of Real-World Data

Ref                            Front Oncol. 2019 Nov 5;9:1178. doi: 10.3389/fonc.2019.01178

PubMed ID:           31750258


Year                          2019

Title                           Discordance of the PAM50 Intrinsic Subtypes Compared With Immunohistochemistry-Based Surrogate in Breast Cancer Patients: Potential Implication of Genomic Alterations of Discordance

Ref                             Cancer Res Treat. 2019 Apr;51(2):737-747. doi: 10.4143/crt.2018.342.

PubMed ID:           30189722


Year                          2019

Title                           PAM50 for Prediction of Response to Neoadjuvant Chemotherapy for ER-positive Breast Cancer

Ref                            Breast Cancer Res Treat. 2018; doi: 10.1007/ s10549-018-5020-7

PubMed Id:            30361874


Year                          2018

Title                           PAM50 Risk of Recurrence Score Predicts 10-Year Distant Recurrence in a Comprehensive Danish Cohort of Postmenopausal Women Allocated to 5 Years of Endocrine Therapy for Hormone Receptor-Positive Early Breast Cancer.

Ref                            J Clin Oncol . 2018 Mar 10;36(8):735-740. doi: 10.1200/JCO.2017.74.6586. Epub 2018 Jan 25

PubMed Id:            29369732


Year                          2018

Title                           Racial Differences in PAM50 Subtypes in the Carolina Breast Cancer Study

Ref                            J Natl Cancer Inst. 2018 Feb 1;110(2):176-182. doi: 10.1093/jnci/djx135

PubMed ID:           28859290


Year                          2018

Title                           Male Breast Cancer: Correlation Between Immunohistochemical Subtyping and PAM50 Intrinsic Subtypes, and the Subsequent Clinical Outcomes

Ref                            Mod Pathol. 2018 Feb;31(2):299-306. doi: 10.1038/modpathol.2017.129.

PubMed ID:           28984296


Year                          2018

Title                           PAM50 and Risk of Recurrence Scores for Interval Breast Cancers

Ref                            Cancer Prev Res (Phila). 2018 Jun;11(6):327-336. doi: 10.1158/1940-6207.CAPR-17-0368.

PubMed ID:           29622545


Year                          2018

Title                           PAM50 Molecular Intrinsic Subtypes in the Nurses' Health Study Cohorts

Ref                            Cancer Epidemiol Biomarkers Prev. 2019 Apr;28(4):798-806. doi: 10.1158/1055-9965.EPI-18-0863.

PubMed ID:           30591591


Year                          2018

Title                           Intrinsic Subtypes and Benefit From Postmastectomy Radiotherapy in Node-Positive Premenopausal Breast Cancer Patients Who Received Adjuvant Chemotherapy - Results From Two Independent Randomized Trials

Ref                            Acta Oncol. 2018 Jan;57(1):38-43.

PubMed ID:           29172851


Year                          2018

Title                           The Ability of PAM50 Risk of Recurrence Score to Predict 10-year Distant Recurrence in Hormone Receptor-Positive Postmenopausal Women With Special Histological Subtypes

Ref                            Acta Oncol. 2018 Jan;57(1):44-50. doi: 10.1080/0284186X.2017.1403044.Epub 2017 Dec 4.

PubMed Id:            29202609


Year                          2018

Title                           The Prosigna Gene Expression Assay and Responsiveness to Adjuvant Cyclophosphamide-Based Chemotherapy in Premenopausal High-Risk Patients With Breast Cancer

Ref                            Breast Cancer Res. 2018 Jul 27;20(1):79. doi: 10.1186/s13058-018-1012-0.

PubMed Id:            30053900


Year                          2017

Title                           Molecular Differences Between Screen-Detected and Interval Breast Cancers Are Largely Explained by PAM50 Subtypes

Ref                            Clin Cancer Res. 2017 May 15;23(10):2584-2592. doi: 10.1158/1078-0432.CCR-16-0967.

PubMed ID:           27587435


Year                          2017

Title                           Prognostic Value of PAM50 and Risk of Recurrence Score in Patients With Early-Stage Breast Cancer With Long-Term Follow-Up

Ref                            Breast Cancer Res. 2017 Nov 14;19(1):120. doi: 10.1186/s13058-017-0911-9.

PubMed ID:           29137653


Year                          2017

Title                           Limitations in Predicting PAM50 Intrinsic Subtype and Risk of Relapse Score With Ki67 in Estrogen Receptor-Positive HER2-negative Breast Cancer

Ref                            Oncotarget. 2017 Mar 28;8(13):21930-21937. doi: 10.18632/oncotarget.15748.

PubMed ID:           28423537


Year                          2017

Title                           PAM50 Provides Prognostic Information When Applied to the Lymph Node Metastases of Advanced Breast Cancer Patients

Ref                            Clin Cancer Res. 2017 Dec 1;23(23):7225-7231. doi: 10.1158/1078-0432.CCR-17-2301.

PubMed ID:           28972041


Year                          2017

Title                           Body Mass Index, PAM50 Subtype, Recurrence, and Survival Among Patients With Nonmetastatic Breast Cancer

Ref                            Cancer. 2017 Jul 1;123(13):2535-2542. doi: 10.1002/cncr.30637.

PubMed ID:           28295245


Year                          2016

Title                           Prognostic Ability of EndoPredict Compared to Research-Based Versions of the PAM50 Risk of Recurrence (ROR) Scores in Node-Positive, Estrogen Receptor-Positive, and HER2-negative Breast Cancer. A GEICAM/9906 Sub-Study

Ref                            Breast Cancer Res Treat. 2016 Feb;156(1):81-9. doi: 10.1007/s10549-016-3725-z

PubMed ID:           26909792


Year                          2016

Title                           PAM50 Gene Signatures and Breast Cancer Prognosis With Adjuvant Anthracycline- And Taxane-Based Chemotherapy: Correlative Analysis of C9741 (Alliance)

Ref                            NPJ Breast Cancer. 2016;2:15023. doi: 10.1038/npjbcancer.2015.23. Epub 2016 Jan 6

PubMed Id:            28691057


Year                          2015

Title                           Response and Survival of Breast Cancer Intrinsic Subtypes Following Multi-Agent Neoadjuvant Chemotherapy

Ref                            Clin Cancer Res. 2016 Feb 1;22(3):560-6. doi: 10.1158/1078-0432.CCR-15-0630. Epub 2015 Jul 7

PubMed Id:            26152740


Year                          2015

Title                           Intrinsic Subtypes, PIK3CA Mutation, and the Degree of Benefit From Adjuvant Trastuzumab in the NSABP B-31 Trial

Ref                            J Clin Oncol. 2015 Apr 20;33(12):1340-7. doi: 10.1200/JCO.2014.56.2439. Epub 2015 Jan 5.

PubMed Id:            25559813


Year                          2015

Title                           Prediction of Late Distant Recurrence After 5 Years of Endocrine Treatment: A Combined Analysis of Patients From the Austrian Breast and Colorectal Cancer Study Group 8 and Arimidex, Tamoxifen Alone or in Combination Randomized Trials Using the PAM50 Risk of Recurrence Score

Ref                            J Clin Oncol. 2015 Mar 10;33(8):916-22.

PubMed Id:            25332252


Year                          2015

Title                           Response and Survival of Breast Cancer Intrinsic Subtypes Following Multi-Agent Neoadjuvant Chemotherapy

Ref                            BMC Med. 2015; 13:303 2015 Dec 18;13:303. doi: 10.1186/s12916-015-0540-z.

PubMed Id:            26684470


Year                          2015

Title                           Prognostic and Predictive Investigation of PAM50 Intrinsic Subtypes in the NCIC CTG MA.21 Phase III Chemotherapy Trial

Ref                            Breast Cancer Res Treat. 2015 Jan;149(2):439-48. doi: 10.1007/s10549-014-3259-1. Epub 2015 Jan 1.

PubMed Id:            25552364


Year                          2015

Title                           Molecular Subtype and Tumor Characteristics of Breast Cancer Metastases as Assessed by Gene Expression Significantly Influence Patient Post-Relapse Survival

Ref                            Ann Oncol. 2015 Jan;26(1):81-8. doi: 10.1093/annonc/mdu498. Epub 2014 Oct 31.                 

PubMed Id:            25361981


Year                          2014

Title                           Intrinsic Subtypes From the PAM50 Gene Expression Assay in a Population-Based Breast Cancer Survivor Cohort: Prognostication of Short- And Long-Term Outcomes

Ref                            Cancer Epidemiol Biomarkers Prev. 2014 May;23(5):725-34. doi: 10.1158/1055-9965.EPI-13-1017. Epub 2014 Feb 12.

PubMed Id:            24521998


Year                          2014

Title                           Predicting Distant Recurrence in Receptor-Positive Breast Cancer Patients With Limited Clinicopathological Risk: Using the PAM50 Risk of Recurrence Score in 1478 Postmenopausal Patients of the ABCSG-8 Trial Treated With Adjuvant Endocrine Therapy Alone

Ref                            Ann Oncol. 2014; 25(2):339-345 2014 Feb;25(2):339-45. doi: 10.1093/annonc/mdt494. Epub 2013 Dec 16.

PubMed Id:            24347518     


Year                          2014

Title                           PAM50 Breast Cancer Intrinsic Subtypes and Effect of Gemcitabine in Advanced Breast Cancer Patients

Ref                            Acta Oncol. 2014 Jun;53(6):776-87. doi: 10.3109/0284186X.2013.865076. Epub 2013 Dec 20.    

PubMed Id:            24359601


Year                          2013              

Title                           Breast Cancer Subtyping by Immunohistochemistry and Histological Grade Outperforms Breast Cancer Intrinsic Subtypes in Predicting Neoadjuvant Chemotherapy Response

Ref                            Breast Cancer Res Treat. 2013 Jul;140(1):63-71. doi: 10.1007/s10549-013-2620-0. Epub 2013 Jul 5

PubMed Id:            23828499


Year                          2013

Title                           Comparison of PAM50 Risk of Recurrence Score With Oncotype DX and IHC4 for Predicting Risk of Distant Recurrence After Endocrine Therapy

Ref                            J Clin Oncol. 2013 Aug 1;31(22):2783-90. doi: 10.1200/JCO.2012.46.1558. Epub 2013 Jul 1.

PubMed Id:            23816962


Year                          2012

Title                           Responsiveness of Intrinsic Subtypes to Adjuvant Anthracycline Substitution in the NCIC.CTG MA.5 Randomized Trial

Ref                            Clin Cancer Res. 2012; 18(8):2402-2412 2012 Apr 15;18(8):2402-12. doi: 10.1158/1078-0432.CCR-11-2956. Epub 2012 Feb 20.

PubMed Id:            22351696     


Year                          2012

Title                           A 50-gene Intrinsic Subtype Classifier for Prognosis and Prediction of Benefit From Adjuvant Tamoxifen

Ref                            Clin Cancer Res. 2012 Aug 15;18(16):4465-72. doi: 10.1158/1078-0432.CCR-12-0286. Epub 2012 Jun 18.

PubMed Id:            22711706     


Year                          2010

Title                           A Comparison of PAM50 Intrinsic Subtyping With Immunohistochemistry and Clinical Prognostic Factors in Tamoxifen-Treated Estrogen Receptor-Positive Breast Cancer

Ref                            Clin Cancer Res. 2010 Nov 1;16(21):5222-32. doi: 10.1158/1078-0432.CCR-10-1282. Epub 2010 Sep 13.

PubMed Id:            20837693


Year                          2009

Title                           Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes

Ref                            J Clin Oncol. 2009 Mar 10;27(8):1160-7. doi: 10.1200/JCO.2008.18.1370. Epub 2009 Feb 9.

PubMed Id:            19204204


This page has been compiled by Sonic Genetics, not by the manufacturers of the Prosigna assay. Responsibility for utilising this information in a patient’s care rests with the managing clinician.

This list was updated in May 2020; corrections and updates would be gratefully received (please contact